Your browser doesn't support javascript.
loading
Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer.
Zhang, Jing; Yang, Wenwei; Liu, Junbao; Wang, Nan; Ren, Zhaoying; Yang, Tingting; Xie, Gongli; Wu, Guifu; Sun, Yongkun.
Afiliação
  • Zhang J; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District Panjiayuan Nanli No. 17, Beijing, 100021, China.
  • Yang W; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District Panjiayuan Nanli No. 17, Beijing, 100021, China.
  • Liu J; Department of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Chaoyang District Shilihe No.352, Beijing, 100122, China.
  • Wang N; Department of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Chaoyang District Shilihe No.352, Beijing, 100122, China.
  • Ren Z; Department of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Chaoyang District Shilihe No.352, Beijing, 100122, China.
  • Yang T; Department of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Chaoyang District Shilihe No.352, Beijing, 100122, China.
  • Xie G; Department of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Chaoyang District Shilihe No.352, Beijing, 100122, China.
  • Wu G; Department of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Chaoyang District Shilihe No.352, Beijing, 100122, China. 414237191@qq.com.
  • Sun Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District Panjiayuan Nanli No. 17, Beijing, 100021, China. hsunyk@cicams.ac.cn.
Invest New Drugs ; 42(4): 454-461, 2024 Aug.
Article em En | MEDLINE | ID: mdl-38990451
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirrolidinas / Timina / Uracila / Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Trifluridina / Combinação de Medicamentos / Bevacizumab / Irinotecano Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Invest New Drugs Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirrolidinas / Timina / Uracila / Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Trifluridina / Combinação de Medicamentos / Bevacizumab / Irinotecano Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Invest New Drugs Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China